FRACTYL HEALTH INC. - COMMON STOCK

Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

28 4 2025 15:30:00 提供 Nasdaq GlobeNewswire

Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation

01 4 2025 06:00:00 提供 Nasdaq GlobeNewswire

Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

03 3 2025 15:05:00 提供 Nasdaq GlobeNewswire

Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025

24 2 2025 06:00:00 提供 Nasdaq GlobeNewswire

Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025

31 1 2025 07:01:00 提供 Nasdaq GlobeNewswire

Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort

13 1 2025 06:00:00 提供 Nasdaq GlobeNewswire

Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

12 12 2024 06:00:00 提供 Nasdaq GlobeNewswire

Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

09 12 2024 06:00:00 提供 Nasdaq GlobeNewswire

Fractyl Health to Participate in the Upcoming December Conferences

26 11 2024 06:00:00 提供 Nasdaq GlobeNewswire

Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates

12 11 2024 15:05:42 提供 Nasdaq GlobeNewswire

Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024

04 11 2024 15:05:00 提供 Nasdaq GlobeNewswire

Fractyl Health Presented New Analysis from Pooled Data of Revita® Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek® 2024

04 11 2024 06:00:00 提供 Nasdaq GlobeNewswire

Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024

29 10 2024 06:00:00 提供 Nasdaq GlobeNewswire

Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024

28 10 2024 06:00:56 提供 Nasdaq GlobeNewswire

Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference

24 9 2024 06:00:58 提供 Nasdaq GlobeNewswire

Fractyl Health to Participate in Upcoming September Investor Conferences

03 9 2024 06:00:52 提供 Nasdaq GlobeNewswire

Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates

14 8 2024 15:05:00 提供 Nasdaq GlobeNewswire

Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita® Endoscopic Procedure

08 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024

07 8 2024 06:00:21 提供 Nasdaq GlobeNewswire

Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs

30 7 2024 06:00:26 提供 Nasdaq GlobeNewswire